Packaging Protein RNA 
Pharmaceutical Technology
AUGUST 17, 2022
Merck (MSD outside North America) has entered a partnership agreement with Orna Therapeutics for discovering, developing and marketing various programmes based on next-generation RNA technology. By self-circularisation, Orna’s oRNA technology makes circular ribonucleic acids (oRNAs) from linear RNAs.
World of DTC Marketing
DECEMBER 29, 2020
Both the Pfizer and Moderna vaccines copied RNA sequence from the virus genome and found a way to manufacture it at scale with high-level processes and quality control. These vaccines were developed using different “platform technologies” that involve slotting genetic material from the virus into a tried and tested delivery package.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Scienmag
MARCH 9, 2022
— Each simple RNA virus has a genome, its “native RNA.” The genome also has the code for making a capsid, the protein shell of a virus that encapsulates the genome and protects it like a nanocontainer. RIVERSIDE, Calif. This genome dictates how the virus replicates in cells to eventually cause disease.
Roots Analysis
OCTOBER 30, 2023
In the past few years, Next Generation RNA therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions.
Scienmag
APRIL 14, 2021
In the cell nucleus histones play a crucial role packaging DNA into chromatin. Histones are however very sticky to both DNA and RNA, so to ensure they are transported to the cell nucleus after synthesis and bind to the right portion of DNA to organize the chromatin, they are guarded by complexes of histone chaperones. […].
pharmaphorum
JUNE 28, 2021
This is the 1st IV infusion of #CRISPR genome editing in patients directly into the bloodstream (target is the liver where the misfolded proteins are made); previously for sickle-cell and beta-thalassemia cells were removed from the body and edited, given back. — Eric Topol (@EricTopol) June 26, 2021.
The Pharma Data
DECEMBER 8, 2020
The company’s product candidates consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, diabetes and lysosomal storage disorders. Laying down a new track for RNA processing, Remix launched with $81 million in financing.
Expert insights. Personalized for you.
147 
Let's personalize your content